Skip to main content

Dabigatran Dosage

Medically reviewed by Drugs.com. Last updated on Jun 12, 2023.

Applies to the following strengths: 75 mg; 110 mg; 150 mg; 20 mg; 30 mg; 40 mg; 50 mg

Usual Adult Dose for Deep Vein Thrombosis - Prophylaxis

Recommended doses: 150 mg orally twice a day

Comments: Generally, the extent of anticoagulation does not need to be assessed with this drug; however, when necessary, use aPTT or ECT, and not INR to assess anticoagulant activity.

Uses: Reduction of risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5 to 10 days; reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism in patients who have been previously treated.

Usual Adult Dose for Prevention of Thromboembolism in Atrial Fibrillation

Recommended doses: 150 mg orally twice a day

Comments: Generally, the extent of anticoagulation does not need to be assessed with this drug; however, when necessary, use aPTT or ECT, and not INR to assess anticoagulant activity.

Uses: Reduction of risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; treatment of deep venous thrombosis and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5 to 10 days; reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism in patients who have been previously treated.

Usual Adult Dose for Deep Vein Thrombosis/Pulmonary Embolism Prophylaxis Following Hip Replacement Surgery

110 mg orally 1 to 4 hours after surgery and after hemostasis has been achieved, then 220 mg orally once a day for 28 to 35 days

Comments: If this drug is not started on the day of surgery, initiate treatment with 220 mg orally once a day after hemostasis has been achieved.

Use: For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery.

Usual Pediatric Dose for Venous Thromboembolism

Weigh-based dosage:


Comments:

Uses:

Renal Dose Adjustments

ADULTS:
To Reduce Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation:


When coadministered with dronedarone or systemic ketoconazole:

Concomitant use with P-gp inhibitors:

For Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism:

Concomitant use with P-gp inhibitors:

Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery:

Concomitant use with P-gp inhibitors:

CHILDREN:

Liver Dose Adjustments

Data not available

Dose Adjustments

When converting patients from warfarin therapy to dabigatran, discontinue warfarin and start dabigatran when the international normalized ratio (INR) is below 2.0.

When converting from dabigatran to warfarin, adjust the starting time of warfarin based on creatinine clearance as follows:
ADULTS:

CHILDREN:

When converting from a parenteral anticoagulant in adult and pediatric patients, start dabigatran 0 to 2 hours before the scheduled administration of the parenteral anticoagulant or at the time of discontinuation of a continuously administered parenteral anticoagulant.

When converting to a parenteral anticoagulant in adults, start the parenteral anticoagulant 12 hours (CrCl 30 mL/min or greater) or 24 hours (CrCl less than 30 mL/min) after the last dose of dabigatran. In pediatric patients, start the parenteral anticoagulant 12 hours after the last dose of dabigatran.

Precautions

US FDA requires a medication guide to assure safe use. For additional information: www.fda.gov/drugs/drug-safety-and-availability/medication-guides

CONTRAINDICATIONS:


US BOXED WARNINGS:

Safety and efficacy of dabigatran capsules have not been established in pediatric patients with non-valvular atrial fibrillation or those who have undergone hip replacement.

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis: Dosing recommendation cannot be provided
Peritoneal dialysis: Data not available

Other Comments

Administration advice:


Storage requirements:

Monitoring:

Patient advice:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.